Ultromics ads

Uncover HFpEF and cardiac amyloidosis from routine echo, with Ultromics' AI. EchoGo® analyses for both conditions in one integrated workflow, flagging disease and delivering additional diagnostic insights to the care team. Powered by clinically validated AI, EchoGo® recognises disease-associated patterns that may be hidden. 600,000+ cases processed. Live in leading U.S. hospitals. Incremental reimbursement. Seamless integration into existing echo workflows. Discover EchoGo®: https://www.ultromics.com/

Clinicians are using Ultromics' AI to uncover HFpEF and cardiac amyloidosis in routine echocardiograms. But what difference is it making in clinical practice? Dr. Faizi Jamal at City of Hope shares his experience integrating EchoGo® Heart Failure and EchoGo® Amyloidosis into the echo workflow. From highlighting suspected disease in scans with no obvious warning signs to providing referring physicians with additional insights, he shares how Ultromics' AI is supporting clinical decisions and guiding the next steps in patient care. Hear it in his words: https://lnkd.in/gKFK5tCr

AI detects HFpEF from routine echocardiography. New findings from the American Heart Association AI Assessment Lab suggest @Ultromics' EchoGo® Heart Failure AI could detect HFpEF significantly earlier than standard care. See the report: https://lnkd.in/g3uUG9wU Learn more about EchoGo® Heart Failure: https://www.ultromics.com/

New independent analysis from the American Heart Association AI Assessment Lab highlights EchoGo® Heart Failure’s potential to identify HFpEF earlier and improve outcomes. Using real-world data from Dandelion Health, the AHA AI Assessment Lab report found EchoGo® could have identified HFpEF an average of 263 days earlier than standard practice. In a cohort of 10,000 patients over five years, earlier identification using EchoGo® Heart Failure could lead to: • 477 lives saved • 406 fewer hospital admissions • 501 fewer readmissions • 564 fewer emergency visits • Up to ~$1.9M in additional health system revenue These findings offer health systems meaningful insight into AI’s impact on outcomes, utilization, and value. Read the full press release to learn more! 🔗 https://lnkd.in/enXxW84T #HFpEF #HeartFailure #AIinCardiology #ClinicalAI #Echocardiography

Ultromics uses FDA-cleared AI to analyze routine echocardiograms to help identify patients with HFpEF and Cardiac Amyloidosis, delivering AI findings directly into existing echo workflows in minutes. Live in top U.S. hospitals. Seamless integration with echo workflows. Incremental reimbursement. Learn more: https://www.ultromics.com/

Ultromics brings clinically validated, AI-powered detection of HFpEF and Cardiac Amyloidosis into routine echocardiography, conditions that can be subtle and complex. EchoGo® analyzes a routinely acquired echo clip and flags HFpEF and CA to support early care decisions. Delivered directly in-workflow in <20 minutes. Available now in the United States.